ICLR
ICON Public Limited Company
There isn't enough reported data to score ICLR yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ICLR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Healthy | |
| Stable |
ICLR's revenue and cash flow are currently healthy, and its profitability and balance sheet are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ICLR PE Valuation
ICLR has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ICLR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect ICLR's earnings, revenue and profitability to hold roughly steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ICLR on the outlook, with more favorable earnings and revenue expectations.
ICLR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.26 | +288% |
| Q4 2025 | $2.90 | -70% |
| Q3 2025 | $7.39 | -18% |
| Q2 2025 | $9.72 | +13% |
| Q1 2025 | $9.18 | +11% |
| Q4 2024 | $9.53 | +29% |
| Q3 2024 | $8.99 | +45% |
| Q2 2024 | $8.60 | +39% |
| Q1 2024 | $8.24 | +33% |
LLY has the stronger earnings trend. Trailing diluted EPS is down 70% for ICLR versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
ICLR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2B | -0.9% |
| Q2 2026 | $2.1B | +2.3% |
| Q1 2026 | $2B | +1.6% |
| Q4 2025 | $8.3B | +304% |
| Q3 2025 | $2B | +0.6% |
| Q2 2025 | $2B | -4.8% |
| Q1 2025 | $2B | -4.3% |
| Q4 2024 | $2B | -1.2% |
ICLR's revenue has picked up after three years of holding roughly level: $2B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.8% | +5.6 points |
| Q2 2026 | 6.7% | -3.7 points |
| Q1 2026 | 8.5% | -2.4 points |
| Q4 2025 | 5.4% | -9.2 points |
| Q3 2025 | 4.2% | -9.8 points |
| Q2 2025 | 10% | -0.5 points |
| Q1 2025 | 11% | -2.7 points |
| Q4 2024 | 15% | +1.7 points |
ICLR's operating margin was 9.8% last quarter, up 5.6 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ICLR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ICLR on profitability, with a higher operating margin.
ICLR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $307.1M | -8% |
| Q2 2026 | $238.8M | +110% |
| Q1 2026 | $136.2M | -43% |
| Q4 2025 | $862M | +211% |
| Q3 2025 | $333.9M | -7.1% |
| Q2 2025 | $113.9M | -38% |
| Q1 2025 | $239.3M | -20% |
| Q4 2024 | $277M | -28% |
ICLR generated $1.5B in free cash flow over the past year, up 60% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ICLR on cash flow, with more consistent year-over-year improvement.
ICLR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +32.7K shares |
| 1 year | -0.9% | -678K shares |
| 3 years | -6.7% | -5.6M shares |
| 5 years | -4.2% | -3.4M shares |
| Available history | +42% | +23.1M shares |
ICLR has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $400M |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $750M |
| Q3 2025 | $250M |
| Q2 2025 | $250M |
| Q1 2025 | $250M |
| Q4 2024 | $400M |
ICLR spent $1.1B buying back its own shares over the past year, about the same as the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ICLR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 2.7x | Moderate |
| Q3 2025 | 2.0x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.0x | Healthy |
| Q4 2024 | 1.8x | Healthy |
| Q3 2024 | 1.7x | Healthy |
| Q2 2024 | 1.8x | Healthy |
| Q1 2024 | 1.9x | Healthy |
ICLR's net debt is about 2.7 years of its operating earnings (EBITDA), up from 1.8 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ICLR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.0 | Neutral |
| Stochastic | 79.3 | Neutral |
ICLR's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ICLR PE vs Healthcare Sector
| Metric | ICLR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ICLR has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ICLR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $183.8 | 9.1% above |
| 20 week MA | $173.9 | 15% above |
| 50 week MA | $152.9 | 31% above |
| 100 week MA | $161.8 | 24% above |
| 200 week MA | $213.5 | 6.1% below |
ICLR has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 6.1% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ICLR on trend strength, trading above more of its moving averages.
ICLR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $171.9 | $192.5 | +12% |
| 2021 | $192.5 | $307.9 | +60% |
| 2022 | $307.9 | $194.9 | -37% |
| 2023 | $194.9 | $283.1 | +45% |
| 2024 | $283.1 | $212.3 | -25% |
| 2025 | $212.3 | $182.8 | -14% |
| 2026 YTD | $182.8 | $200.5 | +9.7% |
ICLR has finished lower in three of the last six years. It's up 9.7% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ICLR on returns for 2026, with the stronger performance.